Skip to main content
Caplight Logo









NuPhase Therapeutics

NuPhase Therapeutics

Private
BeijingHealthcare & Life Scienceshttps://nuphasetx.com

Last Round

Early Funding

Feb 24, 2025

Total Funding Raised

$4.13M

Company Overview

NuPhase Therapeutics is a biotechnology company that focuses on drug discovery by leveraging proprietary liquid-liquid phase separation and high-throughput drug screening platforms to develop targeted therapies for challenging diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

drug discoverybiotechnologyRNA-binding proteinssmall molecule therapeuticsundruggable targetsoncologyphase-separation biologypreclinical developmenthigh-throughput screeningbiotech platformdrug discovery platformbiopharmatherapeutic candidatesdrug discovery startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NuPhase Therapeutics Comparables

Compare NuPhase Therapeutics with similar companies based on industry and business-model similarity.

NuPhase Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Arrakis Therapeutics
81%
Twentyeight-Seven Therapeutics
77%
Transition Bio
70%

NuPhase Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 24, 2025
SeedNov 28, 2024

NuPhase Therapeutics Investors

Notable investors and investment history

NuPhase Therapeutics investors
InvestorRounds
Nest.BioSeed
Proxima Ventures Ltd.Seed, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 28, 2024

    Seed round raised with participation from Nest.Bio and Proxima Ventures.

NuPhase Therapeutics Filings

Explore SEC and related filing metadata, where available.

NuPhase Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NuPhase Therapeutics's valuation, stock price, and market status.

Is NuPhase Therapeutics a public or private company?

NuPhase Therapeutics is a private company.

What is the current stock price of NuPhase Therapeutics?

NuPhase Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NuPhase Therapeutics worth (valuation)?

Valuation information for NuPhase Therapeutics is not publicly available.

Can I buy NuPhase Therapeutics stock?

NuPhase Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NuPhase Therapeutics's last funding round?

NuPhase Therapeutics's most recent funding round was Early Funding on February 24, 2025.

Who are the main investors in NuPhase Therapeutics?

Key investors in NuPhase Therapeutics include Nest Bio Ventures, Proxima Ventures Ltd..

Will NuPhase Therapeutics IPO soon?

No public IPO plans have been announced for NuPhase Therapeutics.

How can I track NuPhase Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NuPhase Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBeijing
Year FoundedN/A
Last FundingFeb 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?